CORUS PHARMA

corus-pharma-logo

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

#Financial #Website #More

CORUS PHARMA

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2001-01-01

Address:
Seattle, Washington, United States

Country:
United States

Website Url:
http://www.coruspharma.com

Total Employee:
501+

Status:
Closed

Total Funding:
150.2 M USD


Investors List

gilead-sciences_image

Gilead Sciences

Gilead Sciences investment in Venture Round - Corus Pharma

washington-research-foundation_image

Washington Research Foundation

Washington Research Foundation investment in Series C - Corus Pharma

hambrecht-quist-capital-management_image

Hambrecht & Quist Capital Management

Hambrecht & Quist Capital Management investment in Series C - Corus Pharma

rbc-capital-markets_image

RBC Capital Markets

RBC Capital Markets investment in Series C - Corus Pharma

bear-stearns-health-innoventures-l-p_image

Bear Stearns Health Innoventures L.P

Bear Stearns Health Innoventures L.P investment in Series C - Corus Pharma

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series C - Corus Pharma

integra-ventures_image

Integra Ventures

Integra Ventures investment in Series C - Corus Pharma

anthem-venture-partners_image

Anthem Venture Partners

Anthem Venture Partners investment in Series C - Corus Pharma

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Corus Pharma

carnegie_image

Carnegie

Carnegie investment in Series C - Corus Pharma

Official Site Inspections

http://www.coruspharma.com

  • Host name: lb-182-253.above.com
  • IP address: 103.224.182.253
  • Location: Australia
  • Latitude: -33.494
  • Longitude: 143.2104
  • Timezone: Australia/Sydney

Loading ...

More informations about "Corus Pharma" on Search Engine